Evoke Pharma announces USPTO granted new patent covering GIMOTI

Evoke Pharma announced that the United States Patent and Trademark Office, USPTO, issued US patent No. 11,517,545 under the title "Treatment of Moderate and Severe Gastroparesis." This patent expires in 2038 and covers the methods for treating moderate-to-severe gastroparesis with metoclopramide via an intranasal route of administration. The patent expands Evoke’s patent portfolio, which includes U.S. Food and Drug Administration Orange Book-listed patents and other patents in the EU, Japan, Canada, and Mexico. "The grant of this patent validates the efficacy signals we observed in our Phase 3 trial results from utilizing nasal metoclopramide to treat patients suffering from moderate-to-severe gastroparesis," commented Matt D’Onofrio, MBA, Chief Business Officer of Evoke Pharma. "We are thrilled to add this new patent to our IP estate, primarily focused on ensuring the long-term availability of our novel product, GIMOTI, to help patients and healthcare providers in need of a revolutionary solution to treat diabetic gastroparesis symptoms," he added.